skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Review

(3157) Views  (1018) Full article downloads

Authors: Jia Li, Muhammad Wasif Saif

Published Date September 2009 Volume 2009:3 Pages 429 - 441
DOI: http://dx.doi.org/10.2147/BTT.S5874

Jia Li, Muhammad Wasif Saif

Yale Cancer Center, Yale School of Medicine, New Haven CT, USA

Abstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.

Keywords: advanced colon cancer, angiogenesis, bevacizumab, chemotherapy, metastatic, targeted therapy, vascular endothelial growth factor, gastric cancer, pancreatic cancer, hepatocellular cancer






 

Other articles by Dr Wasif Saif



Readers of this article also read:

Therapeutic vaccines for malignant brain tumors
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model
Hepatitis B virus and Homo sapiens proteomewide analysis: A profusion of viral peptide overlaps in neuron-specific human proteins
Managing idiopathic short stature: role of somatropin (rDNA origin) for injection
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed